WO2014198880A1 - Composés 2-(2-aminophénoxy)-3-chloronaphthalène-1,4-diones ayant une activité agoniste des récepteurs des orexines de type 2 - Google Patents
Composés 2-(2-aminophénoxy)-3-chloronaphthalène-1,4-diones ayant une activité agoniste des récepteurs des orexines de type 2 Download PDFInfo
- Publication number
- WO2014198880A1 WO2014198880A1 PCT/EP2014/062349 EP2014062349W WO2014198880A1 WO 2014198880 A1 WO2014198880 A1 WO 2014198880A1 EP 2014062349 W EP2014062349 W EP 2014062349W WO 2014198880 A1 WO2014198880 A1 WO 2014198880A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phenyl
- cycloalkyl
- group
- dione
- chloronaphthalene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/59—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
- C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
- C07C217/88—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C217/94—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/22—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C229/64—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
Definitions
- the invention relates to novel 2-(2-aminophenoxy)-3-chloronaphthalene-1 ,4- dione compounds having orexin 2 receptor (OX2R) agonist activity.
- the invention also relates to their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.
- treatment refers to the treatment of a disease or medical condition in a human patient which includes:
- asymmetric 2,3-dichloronaphthalene-1 ,4-diones (II, R 7 — C— C— R 8 fragment ⁇ R 10 — C— C— R 9 fragment) can produce mixtures of final products of formula (I). These mixtures can be separated on the basis of the physico- chemical differences of the constituents, in a known manner, into the pure final products, for example by chromatography, distillation, fractional crystallization, or by the formation of a salt if appropriate or possible under the circumstances.
- Another aspect of the present invention is to provide a pharmaceutical composition containing a compound of formula (I) of the present invention or pharmaceutically acceptable salts, in association with therapeutically inert excipients.
- FBS Fetal Bovine serum
- examples 2-34 were obtained by reacting the appropriate 2,3-dichloro-1 ,4-naphtoquinone compound with the appropriate 2-aminophenol compound. lUPAC names, yields and analytical data are summarized in table 2.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention porte sur un composé de formule (I), dans laquelle R2 à R10 représentent des significations différentes, et sur leurs sels pharmaceutiquement acceptables. L'invention porte également sur des voies de synthèse pour la préparation des composés de formule (I), sur des compositions pharmaceutiques les comprenant, sur leur utilisation comme médicaments, sur leur utilisation comme substances actives thérapeutiques permettant le traitement d'affections à médiation par l'agonisme des récepteurs des orexines de type 2 et sur leur utilisation comme substances actives thérapeutiques permettant le traitement de la narcolepsie, de l'hypersomnie, de l'insomnie nocturne, de la dépression, de l'apnée du sommeil et du décalage horaire, pour favoriser l'état de veille et le réveil après anesthésie et pour la prévention de l'obésité due à un régime alimentaire.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13172105.2 | 2013-06-14 | ||
EP13172105 | 2013-06-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014198880A1 true WO2014198880A1 (fr) | 2014-12-18 |
Family
ID=48625886
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2014/062349 WO2014198880A1 (fr) | 2013-06-14 | 2014-06-13 | Composés 2-(2-aminophénoxy)-3-chloronaphthalène-1,4-diones ayant une activité agoniste des récepteurs des orexines de type 2 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014198880A1 (fr) |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3029024A1 (fr) * | 2014-12-02 | 2016-06-08 | Ferrer Internacional, S.A. | Composés de 2-(2-aminophénoxy)-3-chloronaphthalène-1,4-dione présentant une activité d'agoniste du récepteur d'orexine 2 |
US9676747B2 (en) | 2011-12-21 | 2017-06-13 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
WO2017135306A1 (fr) | 2016-02-04 | 2017-08-10 | Takeda Pharmaceutical Company Limited | Composé de pipéridine substituée et son utilisation |
US9873671B2 (en) | 2014-01-16 | 2018-01-23 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9884818B2 (en) | 2013-05-17 | 2018-02-06 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US9895349B2 (en) | 2013-04-03 | 2018-02-20 | Janssen Sciences Ireland Us | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10071961B2 (en) | 2013-10-23 | 2018-09-11 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10077239B2 (en) | 2015-09-29 | 2018-09-18 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis B antiviral agent |
US10125094B2 (en) | 2013-02-28 | 2018-11-13 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
US10213420B2 (en) | 2014-02-05 | 2019-02-26 | Novira Therapeutics, Inc. | Combination therapy for treatment of HBV infections |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US10441589B2 (en) | 2016-04-15 | 2019-10-15 | Novira Therapeutics, Inc. | Combinations and methods comprising a capsid assembly inhibitor |
US10450270B2 (en) | 2013-07-25 | 2019-10-22 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10537580B2 (en) | 2015-03-19 | 2020-01-21 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis B infections |
US10676429B2 (en) | 2012-08-28 | 2020-06-09 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10973801B2 (en) | 2018-03-14 | 2021-04-13 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
WO2021108628A1 (fr) | 2019-11-25 | 2021-06-03 | Alkermes, Inc. | Composés macrocycliques substitués et méthodes de traitement associées |
US11028048B2 (en) | 2019-01-31 | 2021-06-08 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
US11034700B2 (en) | 2017-03-08 | 2021-06-15 | Takeda Pharmaceutical Company Limited | Substituted pyrrolidine compound and use thereof |
US11059780B2 (en) | 2017-03-08 | 2021-07-13 | Takeda Pharmaceutical Company Limited | Substituted pyrrolidine compound and use thereof |
US11078193B2 (en) | 2014-02-06 | 2021-08-03 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US11096931B2 (en) | 2019-02-22 | 2021-08-24 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
US11319286B2 (en) | 2017-08-03 | 2022-05-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
WO2022140317A1 (fr) | 2020-12-21 | 2022-06-30 | Alkermes, Inc. | Composés pipéridino substitués et procédés de traitement associés |
WO2022140316A1 (fr) | 2020-12-21 | 2022-06-30 | Alkermes, Inc. | Composés macrocycliques substitués et procédés de traitement associés |
US11440883B2 (en) | 2017-08-03 | 2022-09-13 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
WO2022232025A1 (fr) | 2021-04-26 | 2022-11-03 | Alkermes, Inc. | Composés macrocycliques d'amide substitués ayant une activité agoniste du récepteur de l'orexine 2 |
US11491148B2 (en) | 2019-05-06 | 2022-11-08 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
WO2022251304A1 (fr) | 2021-05-26 | 2022-12-01 | Alkerme, Inc. | Composés macrocycliques de carbamate substitués et méthodes de traitement associées |
WO2022251302A1 (fr) | 2021-05-26 | 2022-12-01 | Alkermes, Inc. | Composés macrocycliques bicycliques fusionnés substitués et méthodes de traitement associées |
US11655241B2 (en) | 2018-06-29 | 2023-05-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
US11673867B2 (en) | 2017-12-12 | 2023-06-13 | University Of Tsukuba | Sulfonamide derivative or pharmaceutically acceptable acid-addition salt |
US12071434B2 (en) | 2018-12-12 | 2024-08-27 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US12077522B2 (en) | 2018-06-29 | 2024-09-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
US12091410B2 (en) | 2018-12-12 | 2024-09-17 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8258163B2 (en) | 2008-06-04 | 2012-09-04 | Board Of Regents, The University Of Texas System | Small-molecule agonists for type-2 orexin receptor |
US20120329789A1 (en) * | 2011-06-01 | 2012-12-27 | Wisconsin Alumni Research Foundation | Compositions and methods for treating alzheimers disease |
-
2014
- 2014-06-13 WO PCT/EP2014/062349 patent/WO2014198880A1/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8258163B2 (en) | 2008-06-04 | 2012-09-04 | Board Of Regents, The University Of Texas System | Small-molecule agonists for type-2 orexin receptor |
US20120329789A1 (en) * | 2011-06-01 | 2012-12-27 | Wisconsin Alumni Research Foundation | Compositions and methods for treating alzheimers disease |
Non-Patent Citations (9)
Cited By (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9676747B2 (en) | 2011-12-21 | 2017-06-13 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
US9751857B2 (en) | 2011-12-21 | 2017-09-05 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
US10196376B2 (en) | 2011-12-21 | 2019-02-05 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
US10995064B2 (en) | 2012-08-28 | 2021-05-04 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
US10676429B2 (en) | 2012-08-28 | 2020-06-09 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
US10941113B2 (en) | 2013-02-28 | 2021-03-09 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
US10125094B2 (en) | 2013-02-28 | 2018-11-13 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
US10398677B2 (en) | 2013-04-03 | 2019-09-03 | Janssen Sciences Ireland Uc | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US9895349B2 (en) | 2013-04-03 | 2018-02-20 | Janssen Sciences Ireland Us | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US9884818B2 (en) | 2013-05-17 | 2018-02-06 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10457638B2 (en) | 2013-05-17 | 2019-10-29 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10450270B2 (en) | 2013-07-25 | 2019-10-22 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10071961B2 (en) | 2013-10-23 | 2018-09-11 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10377709B2 (en) | 2013-10-23 | 2019-08-13 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9873671B2 (en) | 2014-01-16 | 2018-01-23 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US10632112B2 (en) | 2014-02-05 | 2020-04-28 | Novira Therapeutics, Inc. | Combination therapy for treatment of HBV infections |
US10213420B2 (en) | 2014-02-05 | 2019-02-26 | Novira Therapeutics, Inc. | Combination therapy for treatment of HBV infections |
US11078193B2 (en) | 2014-02-06 | 2021-08-03 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
EP3029024A1 (fr) * | 2014-12-02 | 2016-06-08 | Ferrer Internacional, S.A. | Composés de 2-(2-aminophénoxy)-3-chloronaphthalène-1,4-dione présentant une activité d'agoniste du récepteur d'orexine 2 |
US10537580B2 (en) | 2015-03-19 | 2020-01-21 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis B infections |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10077239B2 (en) | 2015-09-29 | 2018-09-18 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis B antiviral agent |
WO2017135306A1 (fr) | 2016-02-04 | 2017-08-10 | Takeda Pharmaceutical Company Limited | Composé de pipéridine substituée et son utilisation |
US10898737B2 (en) | 2016-02-04 | 2021-01-26 | Takeda Pharmaceutical Company Limited | Substituted piperidine compound and use thereof |
US10287305B2 (en) | 2016-02-04 | 2019-05-14 | Takeda Pharmaceutical Company Limited | Substituted piperidine compound and use thereof |
EP3984994A1 (fr) | 2016-02-04 | 2022-04-20 | Takeda Pharmaceutical Company Limited | Composé de pipéridine substituée et son utilisation |
US11292766B2 (en) | 2016-02-04 | 2022-04-05 | Takeda Pharmaceutical Company Limited | Substituted piperidine compound and use thereof |
US10508083B2 (en) | 2016-02-04 | 2019-12-17 | Takeda Pharmaceutical Company Limited | Substituted piperidine compound and use thereof |
US10441589B2 (en) | 2016-04-15 | 2019-10-15 | Novira Therapeutics, Inc. | Combinations and methods comprising a capsid assembly inhibitor |
US11129834B2 (en) | 2016-04-15 | 2021-09-28 | Novira Therapeutics, Inc. | Combinations and methods comprising a capsid assembly inhibitor |
US11034700B2 (en) | 2017-03-08 | 2021-06-15 | Takeda Pharmaceutical Company Limited | Substituted pyrrolidine compound and use thereof |
US11059780B2 (en) | 2017-03-08 | 2021-07-13 | Takeda Pharmaceutical Company Limited | Substituted pyrrolidine compound and use thereof |
US11319286B2 (en) | 2017-08-03 | 2022-05-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
US11440883B2 (en) | 2017-08-03 | 2022-09-13 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
US11673867B2 (en) | 2017-12-12 | 2023-06-13 | University Of Tsukuba | Sulfonamide derivative or pharmaceutically acceptable acid-addition salt |
US10973801B2 (en) | 2018-03-14 | 2021-04-13 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
US12077522B2 (en) | 2018-06-29 | 2024-09-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
US11655241B2 (en) | 2018-06-29 | 2023-05-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
US12091410B2 (en) | 2018-12-12 | 2024-09-17 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US12071434B2 (en) | 2018-12-12 | 2024-08-27 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US11028048B2 (en) | 2019-01-31 | 2021-06-08 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
US11096931B2 (en) | 2019-02-22 | 2021-08-24 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
US11491148B2 (en) | 2019-05-06 | 2022-11-08 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
WO2021108628A1 (fr) | 2019-11-25 | 2021-06-03 | Alkermes, Inc. | Composés macrocycliques substitués et méthodes de traitement associées |
WO2022140316A1 (fr) | 2020-12-21 | 2022-06-30 | Alkermes, Inc. | Composés macrocycliques substitués et procédés de traitement associés |
WO2022140317A1 (fr) | 2020-12-21 | 2022-06-30 | Alkermes, Inc. | Composés pipéridino substitués et procédés de traitement associés |
WO2022232025A1 (fr) | 2021-04-26 | 2022-11-03 | Alkermes, Inc. | Composés macrocycliques d'amide substitués ayant une activité agoniste du récepteur de l'orexine 2 |
WO2022251304A1 (fr) | 2021-05-26 | 2022-12-01 | Alkerme, Inc. | Composés macrocycliques de carbamate substitués et méthodes de traitement associées |
WO2022251302A1 (fr) | 2021-05-26 | 2022-12-01 | Alkermes, Inc. | Composés macrocycliques bicycliques fusionnés substitués et méthodes de traitement associées |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014198880A1 (fr) | Composés 2-(2-aminophénoxy)-3-chloronaphthalène-1,4-diones ayant une activité agoniste des récepteurs des orexines de type 2 | |
EP3029024A1 (fr) | Composés de 2-(2-aminophénoxy)-3-chloronaphthalène-1,4-dione présentant une activité d'agoniste du récepteur d'orexine 2 | |
JP7356564B2 (ja) | チエノピリミジンジオンacc阻害剤の固体形態およびその生成のための方法 | |
US20240067600A1 (en) | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | |
EP3303293B1 (fr) | Modulateurs de ror gamma | |
US8088777B2 (en) | Urea derivative | |
JP5277256B2 (ja) | maxi−Kチャネル開口薬としてのピリミジン、ピリジン及びトリアジン誘導体 | |
WO2022116693A1 (fr) | Composé agoniste du récepteur glp-1r et son utilisation | |
EP4141001A1 (fr) | Antagonistes de récepteur kappa-opioïde et produits et procédés associés | |
JP2010208945A (ja) | 複素環化合物 | |
WO2019117148A1 (fr) | Dérivé de sulfonamide ou sel d'addition d'acide pharmaceutiquement acceptable | |
KR20110091508A (ko) | 카르바메이트 화합물 또는 그의 염 | |
JP2015124178A (ja) | 環状アミン誘導体及びその医薬用途 | |
US20240124485A1 (en) | Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity | |
WO2021127459A1 (fr) | Modulateurs du récepteur gpr139 | |
EP2935254A1 (fr) | Composés de 2,3-dihydro-4h-1,3-benzoxazine-4-one, procédé pour leur préparation et forme pharmaceutique comprenant ceux-ci | |
WO2021065893A1 (fr) | Dérivé de tétraline ou sel d'addition d'acide pharmaceutiquement acceptable de celui-ci | |
WO2021169769A1 (fr) | Composé aromatique et composition pharmaceutique et utilisation associées | |
JP2010126496A (ja) | 複素環化合物 | |
WO2020102616A1 (fr) | Inhibiteurs d'acyle et leurs utilisations | |
US20240174689A1 (en) | Substituted carbamate macrocyclic compounds and related methods of treatment | |
US20190135755A1 (en) | Crystal polymorphism of kcnq2-5 channel activator | |
JP5590587B2 (ja) | Npyy5受容体拮抗作用を有する医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14729679 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14729679 Country of ref document: EP Kind code of ref document: A1 |